Together, we can transform the future of cancer care.
Tracking early stage breast cancer with ultrasensitive ctDNA
Information for patients with breast cancer
Monitoring therapy response with ultrasensitive ctDNA across cancer types
Ultrasensitive ctDNA detection in early-stage lung cancer
Personalis is transforming the development of next-generation therapies.
With greater intelligence about cancer and biomarkers comes the potential to unlock the promise of precision oncology. Our proprietary products look deeper into the tumor and its microenvironment, giving you insights that can lead to new innovations.
Our highly sensitive MRD test is designed to detect recurrence earlier than ever before, monitor therapy response, and guide clinical therapy decisions.1-2
Our engine powers individualized neoantigen therapy design and enables patient-specific monitoring of therapy response.3
At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights to deliver advanced insights unique to each patient.1-4
Year Founded
Sq ft Lab & Office Facility
Human Samples Sequenced
Biopharma Partners
Publications & Posters
Issued Patents
QMS & Regulatory Credentials | ISO13485-2016
PRO-1160-v2
